Session

Urothelial cancer

Plenary Session 4

  • Location:
    eURO Auditorium (Hall C1, Level 0)
  • Chairs:
     C.R. Chapple, Sheffield (GB)
     A. Stenzl, Tübingen (DE)
  • Aims and objectives of this session

    The last plenary session of the meeting is devoted to various aspects of urothelial cancer. This includes the treatment and classification of non-muscle invasive bladder cancer, major surgical treatment of advanced urothelial cancer in frail patients as well as systemic treatment of advanced disease and non-urothelial cancer.
    The traditional “Souvenir Session” will conclude the highlights of the 2016 meeting in Munich together with an outlook on various fields in urology for the upcoming years.

Société Internationale d’Urologie (SIU) lecture Non-urothelial bladder cancer
 B.R. Konety
Aims and objectives of this presentation

Non-urothelial bladder cancer comprises approximately 5% of all bladder neoplasms in general. Most common non urothelial tumours include squamous cell carcinoma and adenocarcinoma. This presentation will discuss management of the various non-urothelial forms of bladder cancer and touch upon the distinction between pure non-urothelial tumours and histologic variants of urothelial bladder cancer which may have different biologic behavior and respond to different treatment approaches.

Point-counterpoint session TURBT: Is optical enhancement worth the trouble?
 
 J.A. Witjes, Nijmegen (NL)
No
 K. Thomas, London (GB)
Yes
 P. Gontero, Turin (IT)
Future
 M. Kramer, Lübeck (DE)
State-of-the-art lecture From new genetic and histological classifications to direct treatment
 E. Compérat, Paris (FR)
Aims and objectives of this presentation

New molecular classifications have been discovered recently. Although these classifications are pathology independent, a link between morphology and molecular biology exists. The aim is to include these new findings into daily practice for a better and personalized treatment of our patients.

EAU Guidelines point-counterpoint session Single installation of chemotherapy post TURBT: Statistically significant and also clinically significant?
 
 P-U. Malmström, Uppsala (SE)
Yes
 R.J. Sylvester, Brussels (BE)
No
 L. Türkeri, Istanbul (TR)
Case discussion Making cystectomy safe in the frail patient
 
 C. Stief, Munich (DE)
Surgeon
 I.S. Gill, Los Angeles (US)
Anesthesiologist
 P.Y. Wüthrich, Berne (CH)
Geriatrist
 T.S. O'Brien, London (GB)
Discussion
State-of-the-art lecture Is immunological treatment set to replace chemotherapy in the management of advanced disease?
 T. Powles, London (GB)
State-of-the-art lecture Hematuria: Who really needs investigating and how?
 B.J. Schmitz-Dräger, Fürth (DE)
State-of-the-art lecture 2016 WHO classification of urogential tumours - What's new?
 H. Moch, Zurich (CH)
Aims and objectives of this presentation

The new “Blue Book” of the 2016 World Health Organization (WHO) classification of urogenital tumours contains significant changes, which were discussed at the WHO Consensus Conference in March 2015 in Zurich, Switzerland. The revision of the 2004 WHO urogenital tumour classification was performed by a large group of uropathologists under consideration of new knowledge on pathology, epidemiology and genetics. This presentation will summarise the most important changes of the new WHO classification, including changes from existing tumour types, novel tumours, provisional/emerging tumour entities and novel grading system and/or prognostic groups.

Souvenir session By the EAU Scientific Committee
Benign prostatic disease
 P. Radziszewski, Warsaw (PL)
Urolithiasis and endourology
 T. Knoll, Sindelfingen (DE)
Aims and objectives of this presentation

This lecture will summarise the pearls and news of presentations on all aspects of urinary stone disease and endourology, including pathogenesis, epidemdiology, treatment and intervention.

Renal cancer and transplantation
 A. Alcaraz, Barcelona (ES)
Aims and objectives of this presentation

To review the most interesting data in research, clinical practice and surgery for renal cancer and kidney transplantation.

Prostate cancer: Early detection and screening
 B. Djavan, Vienna (AT)
Aims and objectives of this presentation

a highlight of new and outstanding abstracts and presentations on early detection and screening of prostate cancer

Prostate cancer: Localised and advanced disease
 A. De La Taille, Créteil (FR)
Aims and objectives of this presentation

The goal of the presentation is to review all new informations that physicians can get from EAU meeting on localised and metastatic prostate cancer.

Systemic therapy in GU cancer
 M. De Santis, Coventry (GB)
Aims and objectives of this presentation

This talk will summarise the most interesting results and findings concerning systemic treatment of genitourinary cancers.

Urothelial cancer
 L. Martínez-Piñeiro, San Sebastián de los Reyes (ES)
Aims and objectives of this presentation

Comprehensive summary of the most important presentations (abstracts and non-abstracts) made during this meeting in the area of urothelial cancer.

Functional urology
 D.J.M.K. De Ridder, Leuven (BE)
Aims and objectives of this presentation

The most relevant and innovative abstracts and lectures on functional and female urology will be summarised.

Imaging in urology
 P. Albers, Düsseldorf (DE)
Guideline take home messages
 J. N'Dow, Aberdeen (GB)
Paediatric urology
 W.F.J. Feitz, Nijmegen (NL)
Aims and objectives of this presentation

Paediatric urology overview 2016. New developments in the field and short term future aspects will be presented. Important take home message involves the policy to share, care and cure and European networks for expertise and continuation of care.

Rare diseases in urology
 T.S. O'Brien, London (GB)
Aims and objectives of this presentation

To highlight clinical and research progress in rare diseases across the urological spectrum.

Andrology
 J.O.R. Sonksen, Herlev (DK)
Aims and objectives of this presentation

To give the audience an update on current gold standards and future developments within erectile dysfunction, peyronies disease, hypogonadism and male infertility.

Close